RT Journal Article
T1 Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice.
A1 Lozano-Blázquez, Ana
A1 Calvo-Pita, Cecilia
A1 Carbajales-Álvarez, Mónica
A1 Suárez-Gil, Patricio
A1 Martínez-Martínez, Fernando
A1 Calleja-Hernández, Miguel Ángel
K1 decision-making
K1 drug selection
K1 drug utilization
K1 formulary
K1 neoplasm
K1 Pharmacy and Therapeutics committee
K1 Comité Farmacéutico y Terapéutico
K1 Toma de Decisiones
K1 Utilización de Medicamentos
K1 Formularios Farmacéuticos como Asunto
K1 Formularios de Hospitales
AB BACKGROUNDIn Spain, hospital medicines are assessed and selected by local Pharmacy and Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly important because of their budgetary impact and the sometimes arguable added value with respect to existing alternatives. This study analyzed the PTC drug selection process and the main objective was to evaluate the degree of compliance of prescriptions for oncology drugs with their criteria for use.METHODSThis was a retrospective observational study (May 2007 to April 2010) of PTC-assessed drugs. The variables measured to describe the committee's activity were number of drugs assessed per year and number of drugs included in any of these settings: without restrictions, with criteria for use, and not included in formulary. These drugs were also analyzed by therapeutic group. To assess the degree of compliance of prescriptions, a score was calculated to determine whether prescriptions for bevacizumab, cetuximab, trastuzumab, and bortezomib were issued in accordance with PTC drug use criteria.RESULTSThe PTC received requests for inclusion of 40 drugs, of which 32 were included in the hospital formulary (80.0%). Criteria for use were established for 28 (87.5%) of the drugs included. In total, 293 patients were treated with the four cancer drugs in eight different therapeutic indications. The average prescription compliance scores were as follows: bevacizumab, 83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for non-small-cell lung cancer; cetuximab, 62.0% for colorectal cancer and 50% for head and neck cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and bortezomib, 63.7% for multiple myeloma.CONCLUSIONThe degree of compliance with criteria for use of cancer drugs was reasonably high. PTC functions need to be changed so that they can carry out more innovative tasks, such as monitoring conditions for drug use.
PB Dove Medical Press
YR 2014
FD 2014-07-09
LK http://hdl.handle.net/10668/1903
UL http://hdl.handle.net/10668/1903
LA en
NO Lozano-Blázquez A, Calvo-Pita C, Carbajales-Álvarez M, Suárez-Gil P, Martínez-Martínez F, Calleja-Hernández MÁ. Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice. Ther Clin Risk Manag. 2014; 10:527-35
NO Journal Article;
DS RISalud
RD Apr 7, 2025